Skip to main content
. 2020 Jul 15;156(9):1–5. doi: 10.1001/jamadermatol.2020.2149

Table 3. Response to Ipilimumab and Anti–Programmed Cell Death 1 Therapy.

Response Patients, No. (%)
Ipilimumab therapy Anti–programmed cell death 1 therapy
Complete response 3 (5) 10 (18)
Partial response 5 (9) 14 (25)
Stable disease 15 (27) 13 (23)
Progression 31 (55) 16 (29)
Not evaluated 2 (4) 3 (5)